| TITLE |
DATE |
| Sucampo Promotes Birgit Roerig, Ph.D. to Vice President, Pharmacology
and Toxicology |
8-Dec-2011 |
| Sucampo Pharmaceuticals to Present at Upcoming Health Care Conference |
7-Nov-2011 |
| Sucampo Pharmaceuticals, Inc. Reports Third Quarter 2011 and Year to
Date Financial Results |
3-Nov-2011 |
| Sucampo Appoints Cary J. Claiborne as Chief Financial Officer |
27-Oct-2011 |
| Sucampo Announces Third Quarter 2011 Financial Results and Operating
Highlights Teleconference and Webcast |
27-Oct-2011 |
| Sucampo Pharmaceuticals Invites Investors to Listen to Webcast of
Presentation from BioCentury Conference |
17-Oct-2011 |
| Sucampo Names Greg Deener Vice President of Marketing, Strategy &
Implementation |
20-Sep-2011 |
| Sucampo Announces Stock Repurchase Program |
8-Sep-2011 |
| Sucampo and Numab Sign Drug Discovery Collaboration |
8-Sep-2011 |
| Sucampo Announces R&D Leadership Changes |
7-Sep-2011 |
| Sucampo Appoints Daniel P. Getman, Ph.D. to its Board of Directors |
25-Aug-2011 |
| Sucampo Pharmaceuticals, Inc. Reports Second Quarter 2011 and Year to
Date Financial Results |
4-Aug-2011 |
| Sucampo to Release Second Quarter and Year to Date 2011 Financial
Results and toConduct a Conference Call on August 4, 2011 |
28-Jul-2011 |
| Sucampo AG Names Peter Lichtlen, M.D., Ph.D., Senior Medical Officer
and Vice President of European Operations |
14-Jul-2011 |
| Sucampo Pharmaceuticals, Inc. Reports First Quarter 2011 Financial
Results |
10-May-2011 |
| Phase 3 Clinical Trial Data of Lubiprostone in Japanese Patients with
Chronic Idiopathic Constipation Presented at DDW 2011 |
9-May-2011 |
| Phase 2 Clinical Trial Data of UF-021 in Retinitis Pigmentosa
Patients Presented at ARVO 2011 |
4-May-2011 |
| Sucampo to Release First Quarter 2011 Financial Results and to
Conduct a Conference Call on May 10, 2011 |
3-May-2011 |
| Sucampo Acquires Additional Development and Commercialization Rights to Unoprostone Isopropyl in European Union and Switzerland from R-Tech Ueno |
22-Mar-2011 |
| Sucampo Appoints Interim Chief Financial and Principal Accounting
Officers |
9-Mar-2011 |
| Sucampo Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter
2010 Financial Results |
3-Mar-2011 |
| Sucampo Pharmaceuticals Invites Investors to Listen to Webcast of
Presentation at Cowen Conference |
28-Feb-2011 |
| Sucampo to Release Fourth Quarter and Full Year 2010 Financial
Results and to Conduct a Conference Call on March 3, 2011 |
24-Feb-2011 |
| Sucampo Announces Resignation of Chief Financial Officer |
13-Jan-2011 |
| Sucampo and Takeda Initiate Third Phase 3 Clinical Trial of
Lubiprostone in Opioid-Induced Bowel Dysfunction |
7-Jan-2011 |
| Sucampo Pharmaceuticals, Inc. Acquires Sucampo AG to Strengthen Its
Prostone Intellectual Property Portfolio |
29-Dec-2010 |
| Lubiprostone Successfully Completes Long-Term Phase 3 Safety Trial in
Japanese Patients with Chronic Idiopathic Constipation |
30-Nov-2010 |
| Sucampo Pharmaceuticals Invites Investors to Listen to Webcast from
PiperJaffray Conference |
24-Nov-2010 |
| Sucampo Pharmaceuticals Invites Investors to Listen to Webcast of
Presentation at Credit Suisse Conference |
5-Nov-2010 |
| Sucampo Pharmaceuticals Reports Third Quarter 2010 Financial Results |
3-Nov-2010 |
| Sucampo to Release Third Quarter 2010 Financial Results and Conduct a
Conference Call on November 3, 2010 |
27-Oct-2010 |
| Sucampo Pharmaceuticals Submits Marketing Application to Japanese
Regulatory Authorities for Amitiza (lubiprostone) |
7-Oct-2010 |
| Sucampo Pharmaceuticals Invites Investors to Listen to Webcast of
Presentation at BIO Investor Forum |
1-Oct-2010 |
| Sucampo Pharmaceuticals Reports Second Quarter 2010 Financial Results |
5-Aug-2010 |
| Sucampo to Release Second Quarter 2010 Financial Results and Conduct
a Conference Call on August 5, 2010 |
29-Jul-2010 |
| Lubiprostone Successfully Completes Phase 3 Efficacy Trial in
Japanese Patients Suffering from Chronic Idiopathic Constipation |
8-Jun-2010 |
| R-Tech Ueno Discloses Results of Phase 2 Retinitis Pigmentosa
Clinical Trial |
4-Jun-2010 |
| Data from Clinical Trial Examining Lubiprostone for the Treatment of Opioid-induced Bowel Dysfunction Presented at Digestive Disease Week Conference |
10-May-2010 |
| Sucampo Pharmaceuticals Reports First Quarter 2010 Financial Results |
10-May-2010 |
| Phase 2 Cobiprostone Data Presented at DDW |
3-May-2010 |
| Sucampo to Release First Quarter 2010 Financial Results and Conduct a
Conference Call on May 10, 2010 |
3-May-2010 |
| Sucampo Pharmaceuticals Reports Full Year and Fourth Quarter 2009
Financial Results |
15-Mar-2010 |
| Sucampo to Release Fourth Quarter and Full Year 2009 Financial Results and Conduct a Conference Call on March 15, 2010 |
2-Mar-2010 |
| Sucampo Appoints Thomas J. Knapp as Senior Vice President, General Counsel and Corporate Secretary |
25-Feb-2010 |
| Sucampo Announces Lubiprostone Data Presented at GASTRO 2009 UEGF/WCOG |
25-Nov-2009 |
| Sucampo Receives Marketing Authorization for Amitiza(R) in Switzerland for Treatment of Chronic Idiopathic Constipation |
19-Nov-2009 |
| Sucampo Pharmaceuticals Invites Investors to Listen to Webcast of Presentation at Credit Suisse Conference |
6-Nov-2009 |
| Sucampo Pharmaceuticals Reports Financial Results for the Third Quarter of 2009 |
5-Nov-2009 |
| Sucampo to Release Third Quarter 2009 Financial Results and Conduct a Conference Call on November 5, 2009 |
29-Oct-2009 |
| Sucampo Appoints William L. Ashton to Board of Directors |
20-Oct-2009 |
| Sucampo Adds Chief Operating Officer and Names New Presidents at Americas and European Subsidiaries |
14-Sep-2009 |
| Sucampo Pharmaceuticals Invites Investors to Listen to Webcast of Presentation at Morgan Stanley Conference |
10-Sep-2009 |
| Sucampo Withdraws European Marketing Application for Lubiprostone |
4-Sep-2009 |
| Sucampo Pharmaceuticals Reports Financial Results for the Second Quarter of 2009 |
6-Aug-2009 |
| Sucampo to Release Second Quarter 2009 Financial Results and Conduct a Conference Call on August 6, 2009 |
31-Jul-2009 |
| Takeda and Sucampo Report Top-Line Results of Two Phase 3 Trials of Lubiprostone in Opioid-Induced Bowel Dysfunction |
21-Jul-2009 |
| Sucampo Reports Top-Line Results of Phase 2 Clinical Trial of Cobiprostone for Prevention of NSAID-Induced Gastrointestinal Injuries |
1-Jul-2009 |
| Sucampo Pharmaceuticals Invites Investors to Listen to Webcast of Presentation at Needham Conference |
4-Jun-2009 |
| Sucampo Board of Directors Issues Statement Regarding Sales Performance by Takeda Pharmaceuticals North America for AMITIZA |
28-May-2009 |
| Sucampo Initiates Pivotal Phase 3 Efficacy Trial of Lubiprostone for Chronic Idiopathic Constipation in Japan |
19-May-2009 |
| Sucampo Pharmaceuticals Named Biotechnology Firm of the Year by Tech Council of Maryland |
15-May-2009 |
| Sucampo Pharmaceuticals Reports Results for the First Quarter of 2009 |
7-May-2009 |
| Sucampo to Release First Quarter 2009 Financial Results and Conduct a Conference Call on May 7, 2009 |
30-Apr-2009 |
| Sucampo Acquires Rights to Rescula for U.S. and Canada |
23-Apr-2009 |
| Sucampo Named a Finalist for Tech Council of Maryland's Biotechnology Firm of the Year Award |
6-Apr-2009 |
| Sucampo Pharmaceuticals Invites Investors to Listen to Webcast of Presentation at Cowen Conference |
13-Mar-2009 |
| Sucampo Pharmaceuticals Reports Its Third Consecutive Year of Profitability with Record Full Year 2008 Results |
19-Feb-2009 |
| Sucampo Licenses Lubiprostone in Japan to Abbott |
19-Feb-2009 |
| Sucampo to Release Full Year 2008 Financial Results and Conduct a Conference Call on February 19, 2009 |
9-Feb-2009 |
| Sucampo Completes Enrollment in Its Phase 2 Trial of Cobiprostone for the Prevention of NSAID-Induced Ulcers |
8-Jan-2009 |
| Sucampo Pharmaceuticals Management Reviews Awards Won During 2008 |
24-Dec-2008 |
| Sucampo Initiates Phase 1 Study of SPL-017 for Peripheral Arterial Disease |
18-Dec-2008 |
| Sucampo Strengthens Corporate Structure, Board and Management Team; Approves Stock Buy-Back |
11-Dec-2008 |
| Sucampo Pharmaceuticals to Present at the RBC Capital Markets Healthcare Conference |
9-Dec-2008 |
| Sucampo Pharmaceuticals Selected as a Finalist for Scrip Awards 2008 Pharma Company of the Year - Small and Medium-Sized Enterprises Award |
4-Dec-2008 |
| Sucampo Completes Enrollment in Phase 3 Pivotal Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction |
2-Dec-2008 |
| Sucampo Reports Results for the Third Quarter of 2008 |
12-Nov-2008 |
| Sucampo to Host Third Quarter 2008 Financial Results Conference Call on November 12, 2008 |
5-Nov-2008 |
| Sucampo Europe Presents Long-Term Safety and Efficacy Data of Lubiprostone in Chronic Idiopathic Constipation |
21-Oct-2008 |
| Sucampo Names Stanley G. Miele Head of Sales & Marketing |
16-Oct-2008 |
| Sucampo Pharmaceuticals Invites Investors to Listen to Webcast of Presentation at UBS Conference |
23-Sep-2008 |
| Sucampo Pharmaceuticals Announces Positive Results from a Japanese Phase 2b Dose-Ranging Study of AMITIZA(R) for Chronic Idiopathic Constipation |
18-Sep-2008 |
| Sucampo Pharmaceuticals Limited Appoints New Head of Business Development |
2-Sep-2008 |
| Sucampo Pharmaceuticals Strengthens Its Board of Directors |
27-Aug-2008 |
| Sucampo Pharmaceuticals Appoints Kathryn de Santis as Vice President, Investor Relations and Corporate Communications |
25-Aug-2008 |
| Sucampo Pharmaceuticals Reports Financial Results for the Second Quarter of 2008 |
14-Aug-2008 |
| Sucampo Pharmaceuticals Announces Key Management and Board Appointments at its European Affiliate |
7-Aug-2008 |
| Sucampo Pharmaceuticals to Report Second Quarter 2008 Financial Results on August 14, 2008 |
7-Aug-2008 |
| Sucampo Pharmaceuticals Appoints Jan Smilek Acting Chief Financial Officer |
1-Aug-2008 |
| Sucampo Pharmaceuticals Initiates Phase 2 Trial of Cobiprostone for the Treatment of Portal Hypertension in Patients with Liver Cirrhosis |
28-Jul-2008 |
| Sucampo Pharmaceuticals Appoints Andrew J. Ferrara to its Board of Directors |
22-Jul-2008 |
| Sucampo Pharma Europe Submits Marketing Authorization Application in Switzerland |
9-Jun-2008 |
| AMITIZA(R) (lubiprostone) 8 mcg Now Available to Treat Irritable Bowel Syndrome with Constipation in Adult Women |
27-May-2008 |
| New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) |
18-May-2008 |
| Sucampo Pharma Europe Receives Validation of Marketing Authorization Applications |
15-May-2008 |
| Sucampo Pharmaceuticals Reports Financial Results for the First Quarter of 2008 |
8-May-2008 |
| Sucampo Pharmaceuticals to Host First Quarter 2008 Financial Results Conference Call on May 8, 2008 |
1-May-2008 |
| Sucampo Pharmaceuticals Obtains FDA Approval for AMITIZA(R) for the Treatment of Irritable Bowel Syndrome with Constipation in Adult Women |
29-Apr-2008 |
| Sucampo Pharmaceuticals Reports Financial Results for the Fourth Quarter and Full Year of 2007 |
11-Mar-2008 |
| Sucampo Pharmaceuticals to Host Fourth Quarter and Full Year 2007 Financial Results Conference Call on March 11, 2008 |
4-Mar-2008 |
| Sucampo Pharma Europe Announces the Filing of a Marketing Authorisation Application of Lubiprostone in the United Kingdom with Eight Additional European Countries to Follow |
27-Feb-2008 |
| Sucampo Pharmaceuticals Announces the Initiation of Filings of Marketing Authorization Applications for AMITIZA(R) in Europe |
27-Feb-2008 |
| Sucampo Pharmaceuticals Appoints John C. Wright, Retired Ernst & Young Partner, to Board of Directors |
22-Feb-2008 |
| Sucampo Pharmaceuticals Expands Global Presence as European Subsidiary Opens New Office in Basel, Switzerland |
19-Feb-2008 |
| Sucampo Pharmaceuticals to Present at the 10th Annual BIO CEO and Investor Conference |
8-Feb-2008 |
| Sucampo Pharma, Ltd., a Subsidiary of Sucampo Pharmaceuticals, Inc., Announces Start of Phase 2b Study in Japan to Evaluate Lubiprostone for Chronic Idiopathic Constipation |
29-Nov-2007 |
| Sucampo Pharmaceuticals' Founders Named National Finalists for Ernst & Young Entrepreneur of the Year Award |
19-Nov-2007 |
| Sucampo Pharmaceuticals Reports Financial Results for the Third Quarter of 2007 |
13-Nov-2007 |
| "Move to AMITIZA" Advertising Campaign Underscores the Power of Not Letting Chronic Constipation Slow People Down |
6-Nov-2007 |
| Sucampo Pharma, Ltd., a Subsidiary of Sucampo Pharmaceuticals, Inc. Appoints Kunihiko Soneoka as President and CEO |
5-Nov-2007 |
| Sucampo Pharmaceuticals to Host Third Quarter 2007 Financial Results Conference Call on November 13, 2007 |
1-Nov-2007 |
| Verispan Recognizes Sucampo Pharmaceuticals as a Top 20 Pharmaceutical Company in Promoting to the U.S. Nursing Home Market |
30-Oct-2007 |
| Sucampo Pharmaceuticals to Present at the CIBC World Markets 18th Annual Healthcare Conference |
29-Oct-2007 |
| Sucampo Pharmaceuticals Announces CFO Transition in 2008; Elects New Independent Director |
24-Oct-2007 |
| Sucampo Pharmaceuticals to Open NASDAQ Stock Market on October 22 |
17-Oct-2007 |
| Sucampo Pharmaceuticals Presents Data on Cobiprostone at American College of Gastroenterology Annual Scientific Meeting |
15-Oct-2007 |
| Sucampo Pharmaceuticals Initiates Phase 2, Dose-Finding Trial of Cobiprostone for the Prevention of NSAID-Induced Ulcers in Arthritis Patients |
20-Sep-2007 |
| FDA Accepts Sucampo's sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) |
17-Sep-2007 |
| Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD) |
13-Sep-2007 |
| Sucampo Pharmaceuticals Announces Exercise and Closing of IPO Over-Allotment Option |
29-Aug-2007 |
| Sucampo Pharmaceuticals Reports Financial Results for the Second Quarter of 2007 |
14-Aug-2007 |
| Sucampo Pharmaceuticals Announces Pricing of Initial Public Offering |
2-Aug-2007 |
| Sucampo Pharmaceuticals Submits Supplemental New Drug Application for Lubiprostone to Treat Irritable Bowel Syndrome with Constipation |
12-Jul-2007 |
| Sucampo Pharmaceuticals' Founders Named Ernst & Young Entrepreneur of the Year Award Winners for Greater Washington |
26-Jun-2007 |
| New Study Demonstrates that Lubiprostone May Improve Symptom Relief Rates in Adults with Irritable Bowel Syndrome with Constipation (IBS-C) |
21-May-2007 |
| Sucampo Pharma, Ltd., Initiates Clinical Study of AMITIZA in Japan |
14-Mar-2007 |
| Sucampo Pharmaceuticals Initiates Post-Marketing Studies of AMITIZAŽ in Subjects with Renal or Hepatic Impairment |
13-Mar-2007 |
| Takeda And TAP To Promote Sucampo's Amitiza In The United States |
26-Feb-2007 |
| Sucampo Appoints Veteran Financial Executive Ronald W. Kaiser as Chief Financial Officer |
3-Jan-2007 |
| Sucampo Founder and CEO Ryuji Ueno Receives Japan Innovator Award |
29-Nov-2006 |
| Study Demonstrated AMITIZAŽ (Iubiprostone) Showed Efficacy Within 24 and 48 Hours of Treatment |
23-Oct-2006 |
| AMITIZAŽ (lubiprostone) Phase III Constipation Trial Results Demonstrate Improvements in Symptoms of Irritable Bowel Syndrome with Constipation |
23-Oct-2006 |
| Sucampo Pharmaceuticals Completes Planned Consolidation of European and Asian Affiliates; Announces Strategic Alignment of Senior Management Team |
3-Oct-2006 |
| AMITIZAŽ (lubiprostone) Effective in Treating Chronic Idiopathic Constipation in People Age 65 and Older |
20-Sep-2006 |
| Sucampo's AMITIZAŽ is Finalist for The Scrip Award |
19-Sep-2006 |
| Sucampo Files for Initial Public Offering |
19-Jun-2006 |
| New Study Demonstrates that AMITIZA™ (lubiprostone) May Help Improve Symptoms of Irritable Bowel Syndrome with Constipation |
21-May-2006 |
| AMITIZA™ (Iubiprostone) Shown Effective and Well-Tolerated in People Older than Age 65, a Population Considerably Affected by Chronic Idiopathic Constipation |
21-May-2006 |
| AMITIZA(TM) (lubiprostone), the First Selective Chloride Channel Activator for the Treatment of Chronic Idiopathic Constipation... |
26-Apr-2006 |
| SUCAMPO OBTAINS FDA APPROVAL FOR AMITIZA™ CAPSULES AS TREATMENT FOR CHRONIC IDIOPATHIC CONSTIPATION IN ADULTS |
31-Jan-2006 |
| New Study Found Lubiprostone Increased Spontaneous Bowel Movement Frequency and Improved Symptoms in Patients With Chronic Constipation When Compared to Placebo |
31-Oct-2005 |
| SUCAMPO SELECTS FORMER NOVARTIS SENIOR SALES EXECUTIVE |
12-Oct-2005 |
| SUCAMPO VOLUNTARILY HALTS TACROLIMUS EYE DROPS DEVELOPMENT, FILES COMPLAINT AGAINST BUSINESS PARTNER |
24-Jun-2005 |
| Phase III Clinical Program Evaluates Lubiprostone |
16-May-2005 |
| SUCAMPO RECEIVES $20 MILLION FROM TAKEDA FOR DEVELOPMENT MILESTONE |
16-May-2005 |
| Sucampo and Takeda to enter into an agreement for a new drug, Lubiprostone, for Chronic Constipation and Constipation-predominant irritable bowel syndrome |
1-Nov-2004 |
| A New Management Team is Ready to Go |
30-Sep-2004 |
| Company Co-Founder Is Back as New CEO |
1-Jul-2004 |
| DDW Presentation Shows Sucampo Agent Has No Rebound Effect After Discontinuation Of Treatment For Constipation |
25-May-2004 |
| Sucampo Completes Treatment In A Phase II Safety And Efficacy IBS Study With Its Chloride Channel Activator SPI-0211 |
14-May-2004 |
| Sucampo Pharmaceuticals Appoints Three New Members To Board Of Directors |
6-Apr-2004 |
| Enrollent Complete For Sucampo Phase II Safety And Efficacy Study On Treating IBS WIth Chloride Channel Activator SPI-0211 |
22-Mar-2004 |
| Second Sucampo Phase III Safety Study Confirms Long-term Safety and Effectiveness of SPI-0211 For Treatment of Constipation |
18-Feb-2004 |
| Sucampo Completes Second Phase III Pivotal Efficacy Study for Treatment of Constipation with Proprietary Agent SPI-0211 |
12-Jan-2004 |
| Sucampo Pharmaceuticals Initiates Phase IIa Safety And Efficacy Trial For Proprietary Agent SPI-8811 In Treating Cystic Fibrosis |
22-Sep-2003 |
| Sucampo Completes First Open-Label Safety Study For Treatment Of Constipation With Proprietary Agent SPI-0211 |
15-Sep-2003 |
| Sucampo Completes Enrollment For Phase III Pivital Study Of Treatment of Constipation With Its Proprietary Agent SPI-0211 |
8-Sep-2003 |
| Sucampo Pharmaceuticals Co-founder Ueno to Transition To Full-Time Research Role |
3-Sep-2003 |
| Sucampo Pharmaceuticals Begins Phase II Study for Treatment of Dry Eye Syndrome with Agent FK-506 (Tacrolimus) |
15-Jul-2003 |
| Sucampo Phase III Occasional Constipation Data Presented at Digestive Disease Week 2003 Conference |
19-May-2003 |
| Sucampo Submits IND Application for Proprietary Agent SPI-0211 |
15-May-2003 |
| Sucampo Begins Phase II Study for Treatment of Constipation-Predominant Irritable Bowel Syndrome |
28-Apr-2003 |
| Sucampo Pharmaceuticals Gastrointestinal Compound Shows High Statistical Significance of Primary Endpoint in U.S. Phase III Trial |
12-Nov-2002 |
| Sucampo Announces $4.5 Million Private Placement of Equity with Mizuho and Diamond Capital Co., Ltd. |
11-Oct-2002 |
| Sucampo Initiates Phase II Study with RU-8811 in Non-Alcoholic Steatohepatitis (NASH) Patients |
24-Sep-2002 |
| Sucampo Announces $16 Million Private Placement of Equity With Fujisawa Pharmaceutical Co., Ltd., Orix Corporation and UFJ Capital Co, Ltd. |
8-Aug-2002 |
| Sucampo Group Announces Agreement with Pharmacia, Settles Xalatan Patent Disputes |
29-Apr-2002 |
| Sucampo Announces Exclusive Licensing Agreement with Fujisawa for Ophthalmic Use of Tacrolimus |
19-Feb-2002 |
 |
